This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Eisai Dirección

Dirección controles de criterios 2/4

Información clave

Haruo Naito

Chief Executive Officer (CEO)

JP¥127.0m

Compensación total

Porcentaje del salario del CEO	70.1%
Permanencia del CEO	19.8yrs
Participación del CEO	0.2%
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Haruo Naito en comparación con los beneficios de Eisai?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	n/a	n/a	JP¥27b
Sep 30 2022	n/a	n/a	JP¥32b
Jun 30 2022	n/a	n/a	JP¥33b
Mar 31 2022	JP¥127m	JP¥89m	JP¥48b
Dec 31 2021	n/a	n/a	JP¥57b
Sep 30 2021	n/a	n/a	JP¥63b
Jun 30 2021	n/a	n/a	JP¥60b
Mar 31 2021	JP¥125m	JP¥89m	JP¥42b
Dec 31 2020	n/a	n/a	JP¥94b
Sep 30 2020	n/a	n/a	JP¥121b
Jun 30 2020	n/a	n/a	JP¥125b
Mar 31 2020	JP¥157m	JP¥89m	JP¥122b
Dec 31 2019	n/a	n/a	JP¥97b
Sep 30 2019	n/a	n/a	JP¥58b
Jun 30 2019	n/a	n/a	JP¥73b
Mar 31 2019	JP¥152m	JP¥89m	JP¥63b
Dec 31 2018	n/a	n/a	JP¥64b
Sep 30 2018	n/a	n/a	JP¥66b
Jun 30 2018	n/a	n/a	JP¥54b
Mar 31 2018	n/a	n/a	JP¥52b
Dec 31 2017	n/a	n/a	JP¥29b
Sep 30 2017	n/a	n/a	JP¥30b
Jun 30 2017	n/a	n/a	JP¥29b
Mar 31 2017	JP¥145m	JP¥89m	JP¥39b
Dec 31 2016	n/a	n/a	JP¥55b
Sep 30 2016	n/a	n/a	JP¥72b
Jun 30 2016	n/a	n/a	JP¥69b
Mar 31 2016	JP¥162m	JP¥89m	JP¥55b

Compensación vs. Mercado: Haruo's total compensation ($USD932.57K) is below average for companies of similar size in the German market ($USD4.84M).

Compensación vs. Ingresos: Haruo's compensation has been consistent with company performance over the past year.

CEO

Haruo Naito (75 yo)

19.8yrs

Permanencia

JP¥127,000,000

Compensación

Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Haruo Naito	CEO, Representative Corporate Officer & Director	19.8yrs	JP¥127.00m	0.23% ¥ 33.1m
Gary Hendler	Senior VP & President of EMEA Region	no data	JP¥114.00m	sin datos
Lynn D. Kramer	Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health	no data	JP¥173.00m	sin datos
Yanhui Feng	Senior Vice President	3.2yrs	JP¥124.00m	sin datos
Nadeem Sarwar	President	no data	sin datos	sin datos
Tatsuyuki Yasuno	Senior VP	1.2yrs	sin datos	0.0022% ¥ 324.0k
Kenta Takahashi	Executive VP	no data	sin datos	0.0030% ¥ 438.3k
Yosuke Akita	VP, Chief Compliance Officer & Chief Information Security Officer	1.2yrs	sin datos	0.00055% ¥ 79.6k
Sayoko Sasaki	Vice President of Corporate Communications & ESG	1.2yrs	sin datos	0.0027% ¥ 396.3k
Teruyuki Masaka	VP & Chief HR Officer	1.2yrs	sin datos	0.00055% ¥ 79.6k
Yasushi Okada	Representative Corporate Officer	no data	sin datos	0.0090% ¥ 1.3m
Takashi Owa	Senior VP & Chief Scientific Officer - Japan and Asia Medical Safety	no data	sin datos	0.0035% ¥ 504.8k

1.2yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: EII0's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Haruo Naito	CEO, Representative Corporate Officer & Director	8.8yrs	JP¥127.00m	0.23% ¥ 33.1m
Yasuhiko Katoh	Independent Chairman	6.8yrs	sin datos	0.00052% ¥ 75.2k
Shuzo Kaihori	Independent Outside Director	4.8yrs	sin datos	0.00021% ¥ 30.4k
Fumihiko Ike	Independent Outside Director	1.8yrs	sin datos	0.00035% ¥ 50.6k
Hideki Hayashi	Director	3.8yrs	sin datos	0.013% ¥ 1.9m
Hideyo Uchiyama	Independent Outside Director	4.8yrs	sin datos	0.00021% ¥ 30.4k
Ryota Miura	Independent Outside Director	1.8yrs	sin datos	0.000090% ¥ 13.0k
Hiroyuki Kato	Director	less than a year	sin datos	0.0018% ¥ 256.0k
Yoshiteru Kato	Director	1.8yrs	sin datos	0.0037% ¥ 538.1k
Yumiko Miwa	Independent Outside Director	2.8yrs	sin datos	0.00019% ¥ 27.5k
Richard Thornley	Director	less than a year	sin datos	sin datos

2.8yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: EII0's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

This company listing is no longer active

Eisai Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad